Drug containing hydrogels which release nitric oxide for diabetic wound healing
Award amount
$151,753Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MEDCHEM PARTNERS LLC
- Proposal award date
- 2015-05-01
- Contract end date
- 2016-04-30
- UEI
- S93ZFQLD4ZC7
- Solicitation number
- PA14-058
- Topic code
- NIDDK
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Combating Corneal HSV Infection with Novel Dynasore Analogues
- STTR Phase I: Novel Inhaled Nitric Oxide Therapy For Pulmonary Treatments (COVID-19)
- Dynasore Analogues for Ocular Surface Protection
- A Novel Insulin Pathway Agonist for Alzheimer's Disease
- SBIR Phase I:Ring Contraction Metathesis Reaction for the Generation of Novel Polyene Macrolides
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
6 SBIR/STTR records share this UEI (2010–2024). Reported award amounts total $1,615,287. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, National Science Foundation